Tau oligomers and aggregation in Alzheimer's disease
- PMID: 19943854
- DOI: 10.1111/j.1471-4159.2009.06511.x
Tau oligomers and aggregation in Alzheimer's disease
Abstract
We are analyzing the physiological function of Tau protein and its abnormal pathological behavior when this protein is self-assemble into pathological filaments. These aggregates of Tau protein are the main components in many diseases such as Alzheimer's disease (AD). Recent studies suggest that Tau acquires complex oligomeric conformations which may be toxic. In this review, we emphasized the possible phenomena implicated in the formation of these oligomers. Studies with chemical inductors indicates that the microtubule-binding domain is the most important region involved in Tau aggregation and showed the requirement of a pre-arrange Tau in abnormal conformation to promote self-assembly. Transgenic animal models and AD neuropathology studies showed that post-translational modifications are also implicated in Tau aggregation and neural cell death during AD development. Therefore, we analyzed some events that could be present during Tau aggregation. Finally, we included a brief discussion of the possible relation between glucose metabolism dysfunction in AD, and data of Tau aggregation by using aggregation inhibitors. In conclusion, the process Tau aggregation deserves further investigations to design possible therapeutic targets to inhibit the toxicity of these aggregates and it is possible that could be extended to other diseases with similar etiology.
Similar articles
-
[Significance of tau in the development of Alzheimer's disease].Brain Nerve. 2010 Jul;62(7):701-8. Brain Nerve. 2010. PMID: 20675874 Review. Japanese.
-
Targeting post-translational modifications on tau as a therapeutic strategy for Alzheimer's disease.J Neurogenet. 2011 Dec;25(4):127-33. doi: 10.3109/01677063.2011.626471. J Neurogenet. 2011. PMID: 22091726 Review.
-
Granular tau oligomers as intermediates of tau filaments.Biochemistry. 2007 Mar 27;46(12):3856-61. doi: 10.1021/bi061359o. Epub 2007 Mar 6. Biochemistry. 2007. PMID: 17338548
-
Tau phosphorylation in neuronal cell function and dysfunction.J Cell Sci. 2004 Nov 15;117(Pt 24):5721-9. doi: 10.1242/jcs.01558. J Cell Sci. 2004. PMID: 15537830 Review.
-
Probable participation of 14-3-3 in tau protein oligomerization and aggregation.J Alzheimers Dis. 2011;27(3):467-76. doi: 10.3233/JAD-2011-110692. J Alzheimers Dis. 2011. PMID: 21876254 Review.
Cited by
-
The propagation mechanisms of extracellular tau in Alzheimer's disease.J Neurol. 2022 Mar;269(3):1164-1181. doi: 10.1007/s00415-021-10573-y. Epub 2021 Apr 28. J Neurol. 2022. PMID: 33913022 Review.
-
A post-translational modification signature defines changes in soluble tau correlating with oligomerization in early stage Alzheimer's disease brain.Acta Neuropathol Commun. 2019 Dec 3;7(1):192. doi: 10.1186/s40478-019-0823-2. Acta Neuropathol Commun. 2019. PMID: 31796124 Free PMC article.
-
Generation of nanobodies with conformational specificity for tau oligomers that recognize tau aggregates from human Alzheimer's disease samples.Biomater Sci. 2024 Nov 19;12(23):6033-6046. doi: 10.1039/d4bm00707g. Biomater Sci. 2024. PMID: 39434503 Free PMC article.
-
Exploring the rhodanine universe: Design and synthesis of fluorescent rhodanine-based derivatives as anti-fibrillar and anti-oligomer agents against α-synuclein and 2N4R tau.Bioorg Med Chem. 2024 Dec 15;116:117990. doi: 10.1016/j.bmc.2024.117990. Epub 2024 Nov 9. Bioorg Med Chem. 2024. PMID: 39550891 Free PMC article.
-
Exploring New Structures of Kinase Inhibitors and Multitarget Strategies in Alzheimer's Disease Treatment.Protein Pept Lett. 2025;32(1):2-17. doi: 10.2174/0109298665348075241121071614. Protein Pept Lett. 2025. PMID: 39716791 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical